1
|
Gastaldi S, Boscaro V, Gianquinto E, Sandall CF, Giorgis M, Marini E, Blua F, Gallicchio M, Spyrakis F, MacDonald JA, Bertinaria M. Chemical Modulation of the 1-(Piperidin-4-yl)-1,3-dihydro-2 H-benzo[d]imidazole-2-one Scaffold as a Novel NLRP3 Inhibitor. Molecules 2021; 26:molecules26133975. [PMID: 34209843 PMCID: PMC8271538 DOI: 10.3390/molecules26133975] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2021] [Revised: 06/23/2021] [Accepted: 06/23/2021] [Indexed: 02/06/2023] Open
Abstract
In the search for new chemical scaffolds able to afford NLRP3 inflammasome inhibitors, we used a pharmacophore-hybridization strategy by combining the structure of the acrylic acid derivative INF39 with the 1-(piperidin-4-yl)1,3-dihydro-2H-benzo[d]imidazole-2-one substructure present in HS203873, a recently identified NLRP3 binder. A series of differently modulated benzo[d]imidazole-2-one derivatives were designed and synthesised. The obtained compounds were screened in vitro to test their ability to inhibit NLRP3-dependent pyroptosis and IL-1β release in PMA-differentiated THP-1 cells stimulated with LPS/ATP. The selected compounds were evaluated for their ability to reduce the ATPase activity of human recombinant NLRP3 using a newly developed assay. From this screening, compounds 9, 13 and 18, able to concentration-dependently inhibit IL-1β release in LPS/ATP-stimulated human macrophages, emerged as the most promising NLRP3 inhibitors of the series. Computational simulations were applied for building the first complete model of the NLRP3 inactive state and for identifying possible binding sites available to the tested compounds. The analyses led us to suggest a mechanism of protein–ligand binding that might explain the activity of the compounds.
Collapse
Affiliation(s)
- Simone Gastaldi
- Department of Drug Science and Technology, University of Turin, Via Giuria 9, 10125 Torino, Italy; (S.G.); (V.B.); (E.G.); (M.G.); (E.M.); (F.B.); (M.G.); (F.S.)
| | - Valentina Boscaro
- Department of Drug Science and Technology, University of Turin, Via Giuria 9, 10125 Torino, Italy; (S.G.); (V.B.); (E.G.); (M.G.); (E.M.); (F.B.); (M.G.); (F.S.)
| | - Eleonora Gianquinto
- Department of Drug Science and Technology, University of Turin, Via Giuria 9, 10125 Torino, Italy; (S.G.); (V.B.); (E.G.); (M.G.); (E.M.); (F.B.); (M.G.); (F.S.)
| | - Christina F. Sandall
- Department of Biochemistry & Molecular Biology, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, AB T2N 4Z6, Canada; (C.F.S.); (J.A.M.)
| | - Marta Giorgis
- Department of Drug Science and Technology, University of Turin, Via Giuria 9, 10125 Torino, Italy; (S.G.); (V.B.); (E.G.); (M.G.); (E.M.); (F.B.); (M.G.); (F.S.)
| | - Elisabetta Marini
- Department of Drug Science and Technology, University of Turin, Via Giuria 9, 10125 Torino, Italy; (S.G.); (V.B.); (E.G.); (M.G.); (E.M.); (F.B.); (M.G.); (F.S.)
| | - Federica Blua
- Department of Drug Science and Technology, University of Turin, Via Giuria 9, 10125 Torino, Italy; (S.G.); (V.B.); (E.G.); (M.G.); (E.M.); (F.B.); (M.G.); (F.S.)
| | - Margherita Gallicchio
- Department of Drug Science and Technology, University of Turin, Via Giuria 9, 10125 Torino, Italy; (S.G.); (V.B.); (E.G.); (M.G.); (E.M.); (F.B.); (M.G.); (F.S.)
| | - Francesca Spyrakis
- Department of Drug Science and Technology, University of Turin, Via Giuria 9, 10125 Torino, Italy; (S.G.); (V.B.); (E.G.); (M.G.); (E.M.); (F.B.); (M.G.); (F.S.)
| | - Justin A. MacDonald
- Department of Biochemistry & Molecular Biology, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, AB T2N 4Z6, Canada; (C.F.S.); (J.A.M.)
| | - Massimo Bertinaria
- Department of Drug Science and Technology, University of Turin, Via Giuria 9, 10125 Torino, Italy; (S.G.); (V.B.); (E.G.); (M.G.); (E.M.); (F.B.); (M.G.); (F.S.)
- Correspondence: ; Tel.: +39-011-6707146
| |
Collapse
|
2
|
Sandall CF, Ziehr BK, MacDonald JA. ATP-Binding and Hydrolysis in Inflammasome Activation. Molecules 2020; 25:molecules25194572. [PMID: 33036374 PMCID: PMC7583971 DOI: 10.3390/molecules25194572] [Citation(s) in RCA: 32] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2020] [Revised: 10/02/2020] [Accepted: 10/03/2020] [Indexed: 02/06/2023] Open
Abstract
The prototypical model for NOD-like receptor (NLR) inflammasome assembly includes nucleotide-dependent activation of the NLR downstream of pathogen- or danger-associated molecular pattern (PAMP or DAMP) recognition, followed by nucleation of hetero-oligomeric platforms that lie upstream of inflammatory responses associated with innate immunity. As members of the STAND ATPases, the NLRs are generally thought to share a similar model of ATP-dependent activation and effect. However, recent observations have challenged this paradigm to reveal novel and complex biochemical processes to discern NLRs from other STAND proteins. In this review, we highlight past findings that identify the regulatory importance of conserved ATP-binding and hydrolysis motifs within the nucleotide-binding NACHT domain of NLRs and explore recent breakthroughs that generate connections between NLR protein structure and function. Indeed, newly deposited NLR structures for NLRC4 and NLRP3 have provided unique perspectives on the ATP-dependency of inflammasome activation. Novel molecular dynamic simulations of NLRP3 examined the active site of ADP- and ATP-bound models. The findings support distinctions in nucleotide-binding domain topology with occupancy of ATP or ADP that are in turn disseminated on to the global protein structure. Ultimately, studies continue to reveal how the ATP-binding and hydrolysis properties of NACHT domains in different NLRs integrate with signaling modules and binding partners to control innate immune responses at the molecular level.
Collapse
|
3
|
Platnich JM, Chung H, Lau A, Sandall CF, Bondzi-Simpson A, Chen HM, Komada T, Trotman-Grant AC, Brandelli JR, Chun J, Beck PL, Philpott DJ, Girardin SE, Ho M, Johnson RP, MacDonald JA, Armstrong GD, Muruve DA. Shiga Toxin/Lipopolysaccharide Activates Caspase-4 and Gasdermin D to Trigger Mitochondrial Reactive Oxygen Species Upstream of the NLRP3 Inflammasome. Cell Rep 2019; 25:1525-1536.e7. [PMID: 30404007 DOI: 10.1016/j.celrep.2018.09.071] [Citation(s) in RCA: 105] [Impact Index Per Article: 21.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2017] [Revised: 06/04/2018] [Accepted: 09/21/2018] [Indexed: 01/11/2023] Open
Abstract
The non-canonical caspase-4 and canonical NLRP3 inflammasomes are both activated by intracellular lipopolysaccharide (LPS), but the crosstalk between these two pathways remains unclear. Shiga toxin 2 (Stx2)/LPS complex, from pathogenic enterohemorrhagic Escherichia coli, activates caspase-4, gasdermin D (GSDMD), and the NLRP3 inflammasome in human THP-1 macrophages, but not mouse macrophages that lack the Stx receptor CD77. Stx2/LPS-mediated IL-1β secretion and pyroptosis are dependent on mitochondrial reactive oxygen species (ROS) downstream of the non-canonical caspase-4 inflammasome and cleaved GSDMD, which is enriched at the mitochondria. Blockade of caspase-4 activation and ROS generation as well as GSDMD deficiency significantly reduces Stx2/LPS-induced IL-1β production and pyroptosis. The NLRP3 inflammasome plays a significant role in amplifying Stx2/LPS-induced GSDMD cleavage and pyroptosis, with significant reduction of these responses in NLRP3-deficient THP-1 cells. Together, these data show that Stx2/LPS complex activates the non-canonical inflammasome and mitochondrial ROS upstream of the NLRP3 inflammasome to promote cytokine maturation and pyroptosis.
Collapse
Affiliation(s)
- Jaye M Platnich
- Department of Medicine, University of Calgary, Calgary, AB, Canada; Snyder Institute for Chronic Diseases, University of Calgary, Calgary, AB, Canada
| | - Hyunjae Chung
- Department of Medicine, University of Calgary, Calgary, AB, Canada; Snyder Institute for Chronic Diseases, University of Calgary, Calgary, AB, Canada
| | - Arthur Lau
- Department of Medicine, University of Calgary, Calgary, AB, Canada; Snyder Institute for Chronic Diseases, University of Calgary, Calgary, AB, Canada
| | - Christina F Sandall
- Department of Biochemistry and Molecular Biology, University of Calgary, Calgary, AB, Canada
| | - Adom Bondzi-Simpson
- Department of Medicine, University of Calgary, Calgary, AB, Canada; Snyder Institute for Chronic Diseases, University of Calgary, Calgary, AB, Canada
| | - Huey-Miin Chen
- Department of Biochemistry and Molecular Biology, University of Calgary, Calgary, AB, Canada
| | - Takanori Komada
- Department of Medicine, University of Calgary, Calgary, AB, Canada; Snyder Institute for Chronic Diseases, University of Calgary, Calgary, AB, Canada
| | | | - Jeremy R Brandelli
- Department of Microbiology, Immunology & Infectious Diseases, University of Calgary, Calgary, AB, Canada; Snyder Institute for Chronic Diseases, University of Calgary, Calgary, AB, Canada
| | - Justin Chun
- Department of Medicine, University of Calgary, Calgary, AB, Canada; Snyder Institute for Chronic Diseases, University of Calgary, Calgary, AB, Canada
| | - Paul L Beck
- Department of Medicine, University of Calgary, Calgary, AB, Canada; Snyder Institute for Chronic Diseases, University of Calgary, Calgary, AB, Canada
| | - Dana J Philpott
- Department of Immunology, University of Toronto, Toronto, ON, Canada
| | - Stephen E Girardin
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
| | - May Ho
- Department of Microbiology, Immunology & Infectious Diseases, University of Calgary, Calgary, AB, Canada; Snyder Institute for Chronic Diseases, University of Calgary, Calgary, AB, Canada
| | - Roger P Johnson
- Public Health Agency of Canada, National Microbiology Laboratory, Guelph, ON, Canada
| | - Justin A MacDonald
- Department of Biochemistry and Molecular Biology, University of Calgary, Calgary, AB, Canada
| | - Glen D Armstrong
- Department of Microbiology, Immunology & Infectious Diseases, University of Calgary, Calgary, AB, Canada; Snyder Institute for Chronic Diseases, University of Calgary, Calgary, AB, Canada
| | - Daniel A Muruve
- Department of Medicine, University of Calgary, Calgary, AB, Canada; Snyder Institute for Chronic Diseases, University of Calgary, Calgary, AB, Canada.
| |
Collapse
|
4
|
Hudson G, Flannigan KL, Venu VKP, Alston L, Sandall CF, MacDonald JA, Muruve DA, Chang TKH, Mani S, Hirota SA. Pregnane X Receptor Activation Triggers Rapid ATP Release in Primed Macrophages That Mediates NLRP3 Inflammasome Activation. J Pharmacol Exp Ther 2019; 370:44-53. [PMID: 31004077 PMCID: PMC6542184 DOI: 10.1124/jpet.118.255679] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2018] [Accepted: 04/08/2019] [Indexed: 12/15/2022] Open
Abstract
The pregnane X receptor (PXR) is a ligand-activated nuclear receptor that acts as a xenobiotic sensor, responding to compounds of foreign origin, including pharmaceutical compounds, environmental contaminants, and natural products, to induce transcriptional events that regulate drug detoxification and efflux pathways. As such, the PXR is thought to play a key role in protecting the host from xenobiotic exposure. More recently, the PXR has been reported to regulate the expression of innate immune receptors in the intestine and modulate inflammasome activation in the vasculature. In the current study, we report that activation of the PXR in primed macrophages triggers caspase-1 activation and interleukin-1β release. Mechanistically, we show that this response is nucleotide-binding oligomerization domain, leucine-rich repeat, and pyrin domain-containing 3-dependent and is driven by the rapid efflux of ATP and P2X purinoceptor 7 activation following PXR stimulation, an event that involves pannexin-1 gating, and is sensitive to inhibition of Src-family kinases. Our findings identify a mechanism whereby the PXR drives innate immune signaling, providing a potential link between xenobiotic exposure and the induction of innate inflammatory responses.
Collapse
Affiliation(s)
- Grace Hudson
- Departments of Physiology and Pharmacology (G.H., K.L.F., V.K.P.V., L.A., S.A.H.), Biochemistry and Molecular Biology (C.F.S., J.A.M.), Medicine (D.A.M.), and Immunology, Microbiology, and Infectious Diseases (S.A.H.), University of Calgary, Calgary, Alberta, Canada; Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada (T.K.H.C.); and Department of Medicine, Albert Einstein College of Medicine, Bronx, New York (S.M.)
| | - Kyle L Flannigan
- Departments of Physiology and Pharmacology (G.H., K.L.F., V.K.P.V., L.A., S.A.H.), Biochemistry and Molecular Biology (C.F.S., J.A.M.), Medicine (D.A.M.), and Immunology, Microbiology, and Infectious Diseases (S.A.H.), University of Calgary, Calgary, Alberta, Canada; Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada (T.K.H.C.); and Department of Medicine, Albert Einstein College of Medicine, Bronx, New York (S.M.)
| | - Vivek Krishna Pulakazhi Venu
- Departments of Physiology and Pharmacology (G.H., K.L.F., V.K.P.V., L.A., S.A.H.), Biochemistry and Molecular Biology (C.F.S., J.A.M.), Medicine (D.A.M.), and Immunology, Microbiology, and Infectious Diseases (S.A.H.), University of Calgary, Calgary, Alberta, Canada; Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada (T.K.H.C.); and Department of Medicine, Albert Einstein College of Medicine, Bronx, New York (S.M.)
| | - Laurie Alston
- Departments of Physiology and Pharmacology (G.H., K.L.F., V.K.P.V., L.A., S.A.H.), Biochemistry and Molecular Biology (C.F.S., J.A.M.), Medicine (D.A.M.), and Immunology, Microbiology, and Infectious Diseases (S.A.H.), University of Calgary, Calgary, Alberta, Canada; Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada (T.K.H.C.); and Department of Medicine, Albert Einstein College of Medicine, Bronx, New York (S.M.)
| | - Christina F Sandall
- Departments of Physiology and Pharmacology (G.H., K.L.F., V.K.P.V., L.A., S.A.H.), Biochemistry and Molecular Biology (C.F.S., J.A.M.), Medicine (D.A.M.), and Immunology, Microbiology, and Infectious Diseases (S.A.H.), University of Calgary, Calgary, Alberta, Canada; Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada (T.K.H.C.); and Department of Medicine, Albert Einstein College of Medicine, Bronx, New York (S.M.)
| | - Justin A MacDonald
- Departments of Physiology and Pharmacology (G.H., K.L.F., V.K.P.V., L.A., S.A.H.), Biochemistry and Molecular Biology (C.F.S., J.A.M.), Medicine (D.A.M.), and Immunology, Microbiology, and Infectious Diseases (S.A.H.), University of Calgary, Calgary, Alberta, Canada; Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada (T.K.H.C.); and Department of Medicine, Albert Einstein College of Medicine, Bronx, New York (S.M.)
| | - Daniel A Muruve
- Departments of Physiology and Pharmacology (G.H., K.L.F., V.K.P.V., L.A., S.A.H.), Biochemistry and Molecular Biology (C.F.S., J.A.M.), Medicine (D.A.M.), and Immunology, Microbiology, and Infectious Diseases (S.A.H.), University of Calgary, Calgary, Alberta, Canada; Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada (T.K.H.C.); and Department of Medicine, Albert Einstein College of Medicine, Bronx, New York (S.M.)
| | - Thomas K H Chang
- Departments of Physiology and Pharmacology (G.H., K.L.F., V.K.P.V., L.A., S.A.H.), Biochemistry and Molecular Biology (C.F.S., J.A.M.), Medicine (D.A.M.), and Immunology, Microbiology, and Infectious Diseases (S.A.H.), University of Calgary, Calgary, Alberta, Canada; Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada (T.K.H.C.); and Department of Medicine, Albert Einstein College of Medicine, Bronx, New York (S.M.)
| | - Sridhar Mani
- Departments of Physiology and Pharmacology (G.H., K.L.F., V.K.P.V., L.A., S.A.H.), Biochemistry and Molecular Biology (C.F.S., J.A.M.), Medicine (D.A.M.), and Immunology, Microbiology, and Infectious Diseases (S.A.H.), University of Calgary, Calgary, Alberta, Canada; Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada (T.K.H.C.); and Department of Medicine, Albert Einstein College of Medicine, Bronx, New York (S.M.)
| | - Simon A Hirota
- Departments of Physiology and Pharmacology (G.H., K.L.F., V.K.P.V., L.A., S.A.H.), Biochemistry and Molecular Biology (C.F.S., J.A.M.), Medicine (D.A.M.), and Immunology, Microbiology, and Infectious Diseases (S.A.H.), University of Calgary, Calgary, Alberta, Canada; Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada (T.K.H.C.); and Department of Medicine, Albert Einstein College of Medicine, Bronx, New York (S.M.)
| |
Collapse
|
5
|
Sandall CF, MacDonald JA. Effects of phosphorylation on the NLRP3 inflammasome. Arch Biochem Biophys 2019; 670:43-57. [PMID: 30844378 DOI: 10.1016/j.abb.2019.02.020] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2019] [Revised: 02/22/2019] [Accepted: 02/27/2019] [Indexed: 01/04/2023]
Abstract
The pyrin domain containing Nod-like receptors (NLRPs) are a family of pattern recognition receptors known to regulate an array of immune signaling pathways. Emergent studies demonstrate the potential for regulatory control of inflammasome assembly by phosphorylation, notably NLRP3. Over a dozen phosphorylation sites have been identified for NLRP3 with many more suggested by phosphoproteomic studies of the NLRP family. Well characterized NLRP3 phosphorylation events include Ser198 by c-Jun terminal kinase (JNK), Ser295 by protein kinase D (PKD) and/or protein kinase A (PKA), and Tyr861 by an unknown kinase but is dephosphorylated by protein tyrosine phosphatase non-receptor 22 (PTPN22). Since the PKA- and PKD-dependent phosphorylation of NLRP3 at Ser295 is best characterized, we provide detailed review of this aspect of NLRP3 regulation. Phosphorylation of Ser295 can attenuate ATPase activity as compared to its dephosphorylated counterpart, and this event is likely unique to NLRP3. In silico modeling of NLRP3 is useful in predicting how Ser295 phosphorylation might impact upon the structural topology of the ATP-binding domain to influence catalytic activity. It is important to gain as complete understanding as possible of the complex phosphorylation-mediated mechanisms of regulation for NLRP3 in part because of its involvement in many pathological processes.
Collapse
Affiliation(s)
- Christina F Sandall
- Department of Biochemistry & Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, AB, T2N 4Z6, Canada
| | - Justin A MacDonald
- Department of Biochemistry & Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, AB, T2N 4Z6, Canada.
| |
Collapse
|
6
|
Lau A, Chung H, Komada T, Platnich JM, Sandall CF, Choudhury SR, Chun J, Naumenko V, Surewaard BG, Nelson MC, Ulke-Lemée A, Beck PL, Benediktsson H, Jevnikar AM, Snelgrove SL, Hickey MJ, Senger DL, James MT, Macdonald JA, Kubes P, Jenne CN, Muruve DA. Renal immune surveillance and dipeptidase-1 contribute to contrast-induced acute kidney injury. J Clin Invest 2018; 128:2894-2913. [PMID: 29863495 DOI: 10.1172/jci96640] [Citation(s) in RCA: 62] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2017] [Accepted: 04/10/2018] [Indexed: 01/04/2023] Open
Abstract
Radiographic contrast agents cause acute kidney injury (AKI), yet the underlying pathogenesis is poorly understood. Nod-like receptor pyrin containing 3-deficient (Nlrp3-deficient) mice displayed reduced epithelial cell injury and inflammation in the kidney in a model of contrast-induced AKI (CI-AKI). Unexpectedly, contrast agents directly induced tubular epithelial cell death in vitro that was not dependent on Nlrp3. Rather, contrast agents activated the canonical Nlrp3 inflammasome in macrophages. Intravital microscopy revealed diatrizoate (DTA) uptake within minutes in perivascular CX3CR1+ resident phagocytes in the kidney. Following rapid filtration into the tubular luminal space, DTA was reabsorbed and concentrated in tubular epithelial cells via the brush border enzyme dipeptidase-1 in volume-depleted but not euvolemic mice. LysM-GFP+ macrophages recruited to the kidney interstitial space ingested contrast material transported from the urine via direct interactions with tubules. CI-AKI was dependent on resident renal phagocytes, IL-1, leukocyte recruitment, and dipeptidase-1. Levels of the inflammasome-related urinary biomarkers IL-18 and caspase-1 were increased immediately following contrast administration in patients undergoing coronary angiography, consistent with the acute renal effects observed in mice. Taken together, these data show that CI-AKI is a multistep process that involves immune surveillance by resident and infiltrating renal phagocytes, Nlrp3-dependent inflammation, and the tubular reabsorption of contrast via dipeptidase-1.
Collapse
Affiliation(s)
- Arthur Lau
- Department of Medicine.,Snyder Institute for Chronic Diseases
| | - Hyunjae Chung
- Department of Medicine.,Snyder Institute for Chronic Diseases
| | - Takanori Komada
- Department of Medicine.,Snyder Institute for Chronic Diseases
| | - Jaye M Platnich
- Department of Medicine.,Snyder Institute for Chronic Diseases
| | - Christina F Sandall
- Department of Biochemistry and Molecular Biology.,Libin Cardiovascular Institute of Alberta
| | | | - Justin Chun
- Department of Medicine.,Snyder Institute for Chronic Diseases
| | - Victor Naumenko
- Snyder Institute for Chronic Diseases.,Department of Microbiology, Immunology, and Infectious Diseases, and
| | - Bas Gj Surewaard
- Snyder Institute for Chronic Diseases.,Department of Microbiology, Immunology, and Infectious Diseases, and
| | | | - Annegret Ulke-Lemée
- Department of Biochemistry and Molecular Biology.,Libin Cardiovascular Institute of Alberta
| | - Paul L Beck
- Department of Medicine.,Snyder Institute for Chronic Diseases
| | - Hallgrimur Benediktsson
- Snyder Institute for Chronic Diseases.,Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Anthony M Jevnikar
- Department of Medicine, University of Western Ontario, London, Ontario, Canada
| | - Sarah L Snelgrove
- Centre for Inflammatory Diseases, Monash University Department of Medicine, Monash Medical Centre, Clayton, Victoria, Australia
| | - Michael J Hickey
- Centre for Inflammatory Diseases, Monash University Department of Medicine, Monash Medical Centre, Clayton, Victoria, Australia
| | - Donna L Senger
- Department of Oncology.,Arnie Charbonneau Cancer Institute
| | - Matthew T James
- Department of Medicine.,Libin Cardiovascular Institute of Alberta
| | - Justin A Macdonald
- Department of Biochemistry and Molecular Biology.,Libin Cardiovascular Institute of Alberta
| | - Paul Kubes
- Snyder Institute for Chronic Diseases.,Department of Microbiology, Immunology, and Infectious Diseases, and
| | - Craig N Jenne
- Snyder Institute for Chronic Diseases.,Department of Microbiology, Immunology, and Infectious Diseases, and
| | - Daniel A Muruve
- Department of Medicine.,Snyder Institute for Chronic Diseases
| |
Collapse
|